AbbVie Extends Rinvoq Exclusivity to 2037, Delaying Generics in U.S.

AbbVie has settled patent litigation with all generic manufacturers seeking FDA approval for generic versions of Rinvoq, effectively delaying generic entry until April 2037—four years later than previously expected.123

The original U.S. patent expiry for Rinvoq was anticipated in 2033, but settlements with major generics (Sandoz, Hetero Labs, Aurobindo Pharma, Intas, Sun Pharmaceuticals) have extended exclusivity.2

AbbVie’s shares reached record highs following the announcement, reflecting investor optimism and the importance of Rinvoq, which generated $3.75 billion in global sales in the first half of 2025 and is now expected to contribute $11 billion in 2027.123

The legal settlements mark the end of litigation initiated in 2023 for alleged patent infringement by the generics companies.2

Wells Fargo and other analysts describe this as a "big win" for AbbVie, securing a longer revenue runway for Rinvoq, which is critical to AbbVie’s growth strategy after the loss of exclusivity for Humira.23

Sources:

1. https://www.zacks.com/stock/news/2750667/abbvie-settles-rinvoq-patent-dispute-what-it-means-for-the-stock

2. https://www.pharmaceutical-technology.com/news/abbvie-extends-rinvoq-exclusivity-by-four-years-after-generics-settlements/

3. https://stocktwits.com/news-articles/markets/equity/abbvie-stock-touches-record-high-after-company-dismisses-generic-competition-for-rinvoq-till-2037/chwNAqPRdwG